25 Background: Population-based, prospective studies can provide important insights into 26 Parkinson's disease (PD) and other parkinsonian disorders. Participant follow-up in such 27 studies is often achieved through linkage to routinely-collected healthcare datasets. We 28 systematically reviewed the published literature on the accuracy of these datasets for this 29 purpose.
. A flow diagram of the study 143 selection process is shown in Fig 1. We obtained key additional information from the 144 authors of two studies [20, 24] . Of the 18 included articles, 13 reported PPV [11, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , four 145 reported sensitivity [25] [26] [27] [28] and one reported both [12] . Four articles contained more than 146 one study [11] [12] [13] 17 ]. One of these consisted of multiple sub-studies, using different 147 methods to evaluate datasets across several countries, so we included these as six separate . Four studies, including the three that evaluated prescription data, did
228 not specify the coding system used [11, 17, 21, 28] .
229
The diagnostic coding position assessed also varied. Three studies assessed primary Table S3 ). The commonest concerns were:
238 selection bias, lack of reporting of the codes used to identify disease cases, insufficiently 239 rigorous reference standards, inappropriate inclusions and exclusions, or patients being lost 240 to follow-up.
242 Positive predictive value
243 For PD, there were 17 PPV estimates in total (Fig 2) Several within-study comparisons were available from three studies identifying PD 261 (Table 3) 
271
For parkinsonism there were 10 PPV estimates in total (Fig 2) 300 For PD, there were 11 sensitivity estimates in total (Fig 3) [12,25-28]. Of these, nine were 301 sensitivity estimates for mortality data alone, consistently showing that codes in the primary 302 position only gave low sensitivities of 11-23%, rising to 53-60% when codes from any 303 position were included[12,25-28]. A single study reported the sensitivity of hospital data to 304 be 73%, increasing to 83% when hospital and mortality data were combined. There were no 305 sensitivity estimates for primary care or prescription data.
306
For parkinsonism, there were three sensitivity estimates, all from one study [12] .
307 Hospital admissions and mortality data combined gave higher sensitivity (71%) compared 308 with either mortality or hospital data alone (43% and 63% respectively). 392 therefore include diagnoses made by specialists, thus increasing their accuracy. We found 393 only one small study of primary care data, reporting a promising PPV of 81%, improving to 394 90% with the inclusion of medication codes [20] . No studies investigated the sensitivity of 395 primary care data. Further research into the accuracy of primary care data is needed.
396
Two studies investigated using algorithmic combinations of codes from different 397 sources to improve PPV [12, 16] . These investigated the additional benefit of the inclusion of 398 factors such as only including codes that appeared more than once, selecting codes in the 399 primary position only, combining diagnostic codes with prescription data, and only including 400 diagnoses made in specialist clinics. These methods increased PPV but at a cost to the 401 number of cases identified. The development of algorithms that maximize PPV whilst 402 maintaining a reasonable sensitivity (e.g., by combining multiple complimentary datasets)
403 merits further evaluation.
404
To our knowledge, no studies have evaluated the accuracy of routinely-collected 405 healthcare data for solely identifying atypical parkinsonian syndromes such as PSP and MSA.
406 Further work is needed to understand whether these datasets provide a valuable resource 407 for studying these less common diseases. 
